Why the study?
Does intravenous eptifibatide inhibit ex vivo platelet adhesion and aggregation in patients undergoing angioplasty?
Population
6 patients undergoing angioplasty
Comparison
Intravenous eptifibatide 0.75 micrograms/kg/min… vs Baseline blood samples from the same patients
Design
Preclinical
Follow-up
24-48 hours post-infusion
Authors
Loading...
Requires human validation before angioplasty use; leaves open translation of eptifibatide effects from animal models.
Does intravenous eptifibatide inhibit ex vivo platelet adhesion and aggregation in patients undergoing angioplasty?
Eptifibatide provides potent but rapidly reversible inhibition of shear-induced platelet aggregation in patients undergoing angioplasty.
Kamat et al. (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: